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ABSTRACT 
We conducted a European-only and trans-ancestral genome‐wide association meta-
analysis in 72,147 stroke patients and 823,869 controls using data from UK Biobank 
(UKB) and the MEGASTROKE consortium. We identified an exonic polymorphism in 
NOS3 (rs1799983, p.Glu298Asp; p=2.2E-8; OR=1.05[1.04-1.07]) and variants in an intron 
of COL4A1 (rs9521634, p-value=3.8E-8, OR=1.04[1.03-1.06]) and near DYRK1A 
(rs720470, p=6.1E-9; OR=1.05[1.03-1.07]) at genome-wide significance for stroke. Effect 
sizes of known stroke loci were highly correlated between UKB and MEGASTROKE. 
Using Mendelian Randomization we further show that genetic variation in the nitric oxide 
synthase (NOS) – nitric oxide (NO) pathway in part affects stroke risk via variation in 
blood pressure.  
 
INTRODUCTION 
Stroke is the leading cause of disability and the second most common cause of death 
worldwide. The identification of common genetic variants for vascular conditions has 
provided mechanistic insights, improved options for risk prediction, and facilitated the 
development of novel therapeutics .
1
 The MEGASTROKE consortium recently reported on 
the largest genome-wide association study (GWAS) to date in >520,000 subjects from 
multiple ethnicities.
2
 Aside from finding novel risk loci for any stroke (AS), any ischemic 
stroke (AIS) and ischemic stroke subtypes , this study demonstrated marked genetic 
overlap with related vascular traits. Still, much of the heritability of stroke remains  
unexplained and the biological mechanisms and pathways underlying shared genetic 
influences with related traits are largely elusive. 
The UK Biobank (UKB) was established to improve understanding of common diseases 
including stroke. Participants were recruited from the general adult population and, in 
addition to having provided self-reported medical history at recruitment, are followed 
prospectively, chiefly through linkage to their National Health Service 
records.
3
(http://www.ukbiobank.ac.uk) UKB recently released genotypes on over 500,000 
participants thus adding to available GWAS data.  
The current study aimed to identify additional susceptibility loci for stroke and obtain 
further insights into relevant pathways by meta -analyzing GWAS summary statistics from 
UKB with data from the MEGASTROKE European-only stratum followed by a trans-
ancestral analysis. 
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SUBJECTS AND METHODS 
The protocol for this study received prior approval by all IRBs, and informed consent was 
obtained from each subject. 
 
UK Biobank 
For definition of stroke cases we used UKB fields 42007 and 42009, the algorithmically 
defined stroke outcome, including both prevalent strokes (stroke prior to recruitment) and 
incident strokes (first stroke diagnosed during follow-up) 
(http://biobank.ctsu.ox.ac.uk/crystal/docs/alg_outcome_stroke.pdf ). Stroke events that 
were self-reported only without corroborating evidence from medical records were 
excluded due to substantial uncertainty about the accuracy of stroke self-report.
4
 Coded 
hospital admissions and death record data (ICD 9 and 10 coding systems) were included 
based on previous work showing good accuracy of these data sources for identifying 
stroke cases.
5
 Participants without a stroke diagnosis were included as controls.  Related 
participants and those of non-White-British descent were excluded, as were SNPs with 
MAF <0.01. The final UKB dataset consisted of 4,985 AS cases, 3,628 AIS cases and 
369,419 controls. The genetics dataset of UKB is described at 
https://www.biorxiv.org/content/early/2017/07/20/166298 .  We fitted a logistic regression 
model with stroke as the outcome and each SNP as a dependent variable including age, 
sex, principal components 1-10, and genotyping chip as covariates. 
 
MEGASTROKE 
We used the full summary statistics from MEGASTROKE after filtering as recently 
described. Analyses included 67,162 AS cases, 60,341 AIS cases, 6,688 large artery stroke 
(LAS) cases, 9,006 cardioembolic stroke (CES) cases and 11,710 small vessel stroke 
(SVS) cases.
2
 
 
Genome-wide association meta-analyses 
We first performed a fixed-effects meta-analysis for AS and AIS using summary statistics 
from UKB and the European stratum from MEGASTROKE. The newly formed European 
stratum was then meta-analyzed with the East Asian, South Asian, African American, 
other Asian, and Latin American strata from MEGASTROKE using a fixed-effects model. 
The final dataset consisted of 72,147 AS cases (45,570 European), 63,969 AIS cases 
(37,845 European) and 823,869 controls (775,530 European).  Single genomic control was 
applied for all analyses. We report on results from both the new European-only meta-
analysis and the trans-ancestral meta-analysis. Genome-wide significance was set at p<5E-
8. 
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Mendelian Randomization analysis 
To evaluate the causal association of  recently published variants in the NOS3 pathway
6
 
and stroke risk, we performed a two-sample Mendelian Randomisation (MR) analysis 
using blood pressure (BP) data from UKB as an exposure variable (systolic BP [SBP] and 
diastolic BP [DBP]: 318,417 subjects analyzed using a BOLT LMM model) and stroke 
data from the combined European-only analysis as outcome. We used the R package 
“mendelianRandomization” and report on results obtained from the weighted median, 
inverse variance weighted, MR-EGGER, and MBE (modal) method. 
 
Expression quantitative trait loci (eQTLs) 
For lead variants at the novel loci  and SNPs in LD (r
2
>0.8) we queried publicly available 
eQTL databases GTEx7
7
 and GRASP2.
8
 
 
 
RESULTS 
 
We first compared effect sizes and directions of previously published lead SNPs from 
MEGASTROKE between UKB and the European MEGASTROKE stratum. Two low-
frequency variants at RGS7 and TMF4SF4 were not available in UKB leaving 30 loci for 
analysis. We observed significant positive correlations in the effect sizes for both AS 
(r=0.56 [0.26-0.76], p=0.0011) and AIS (r=0.62 [0.34-0.80], p=0.00021) between the two 
datasets, thus supporting our approach of meta-analyzing them.  
Fixed-effects meta-analysis of the UKB and MEGASTROKE datasets (up to 72,147 cases 
and 823,869 controls) revealed 3 novel loci reaching genome-wide significance (p<5E-8) 
for association with AS in the European-only or the full trans-ancestral analysis (Table 1 
and Figure 1A). Genomic inflation was estimated to be 1.05 both for AS and AIS 
(Europeans-only analysis). For the transethnic analyses, we found lambda values of 1.04 
and 1.07, respectively. The explained phenotypic variance of the three novel loci is 
estimated to be 0.06% for AS in Europeans assuming a disease prevalence of 0.055. 
The first finding is an exonic SNP in the Nitric Oxide Synthase 3 (NOS3) gene 
(rs1799983, p.Glu298Asp) that was associated with AS in the European-only analysis 
(p=2.2E-8; OR=1.05 [1.04-1.07]; Table 1 and Figure 1B). Functional variants in NOS3 
and other genes of the NOS-NO pathway have been associated with hypertension.
6
 Hence, 
we explored the possibility that the effects of genetically determined dysregulation of the 
NOS-NO pathway on stroke risk are mediated via BP using a two-sample MR analysis. We 
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selected instruments in the genes encoding proteins in the NOS -NO pathway that exert 
known functional effects on NO signaling, as summarized in a recent review
6
. The genetic 
instruments included variants in NOS3 (rs1799983, rs2070744, rs3918226), Guanylate 
Cyclase 1, Soluble Alpha 3 GUCY1A3 (rs7692387), and the L-arginine transporter gene 
SLC7A1 (rs41318021)
6
; rs7539120 in the Nitric oxide synthase 1 adaptor protein gene 
NOS1AP was not available for analysis in UKB. Considering BP in UKB as the exposure 
and AS as outcome we found significant associations in the weighted median approach 
(OR=1.11, p<0.0001  for SBP; OR=1.14, p<0.0001  for DBP) and IVW (OR=1.15, 
p=0.005 for SBP; OR=1.19, p=0.002 for DBP), suggesting a causal association of the 
instruments with stroke via BP (Figure 2) with an estimated contribution
9
 of 4%. We 
found no evidence of heterogeneity in the IVW analyses and the intercept in the MR -
Egger analyses were not significant (all p>0.10) suggesting absence of significant 
pleiotropy. After excluding two potentially pleiotropic SNPs identified through 
PhenoScanner as being associated with CAD (rs3918226, rs7692387), the results remained 
significant. 
We further found variants in COL4A1 to be associated with AS (rs9521634, trans-
ancestral analysis: p=3.8E-8; OR=1.04 [1.03-1.06], Table 1 and Figure 1C). rs9521634 is 
situated in intron 28 but does not act as a known eQTL for  any gene in available tissues as 
is also true for SNPs in linkage disequilibrium (LD, r
2
>0.8) with rs9521634. 
The third locus resides in the intergenic region between DYRK1A and KCNJ6 (rs720470, 
p=6.1E-9; OR=1.05 [1.03-1.07], Table 1 and Figure 1D). rs720470 serves as an eQTL for 
DYRK1A in whole blood (p=9E-4),
10
  thus identifying DYRK1A as a plausible causal gene 
at this locus. 
Association results for ischemic stroke subtypes were available from MEGASTROKE. 
rs1799983 in NOS3 showed the strongest association with CES (p=4.6E-5, OR=1.09 [1.04-
1.13]; p>0.1 for both SVS and LAS) whereas rs9521634 in COL4A1 showed the strongest 
association with SVS (p=0.0004, OR=1.06[1.03-1.10]; p>0.3 for CES and LAS). There 
was no clear association signal for ischemic stroke subtypes at DYRK1A (all p>0.01). 
 
 
DISCUSSION 
 
We found rs1799983 encoding p.Glu298Asp in endothelial NOS to reach genome-wide 
significance for association with AS. Nitric oxide signaling is a key regulator of vascular 
tone, BP, and platelet aggregation.  p.Glu298Asp lowers eNOS activity by disruption of 
eNOS caveolar localization
11
. Another variant, rs3918226, that is situated in the NOS3 
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promoter and was found to lower promoter activity
12
, has been shown to associate with 
both hypertension
12
 and coronary artery disease.
13
 rs3918226 is in low LD (r
2
=0.17) with 
our lead SNP and did not reach genome-wide significance for association with AS or AIS. 
Still, our MR analysis suggests that the aggregate effects of common variants in the NOS-
NO pathway on stroke risk are in part mediated through blood pressure. Similar results 
have recently been shown for coronary artery di sease using a genetic risk score comprised 
of two common variants in NOS3 and GUCY1A3.
14
 Somewhat surprisingly, we found the 
strongest association with CES. While this might relate to limited power in stroke 
subtypes, potential mechanisms underlying this association might include prothrombotic 
effects as well as mechanism that are yet unknown.  
 
Our findings further highlight a role of COL4A1 in stroke. Collagen type IV α1 is a major 
constituent of the vascular basement membrane and forms heterotrimers with collagen IV 
α2. Rare variants in COL4A1 cause monogenic small vessel disease with hemorrhagic and 
ischemic stroke being part of the spectrum.
15,  16
. These mutations are associated with 
structural protein changes or altered expression levels of COL4A1, which interfere with 
the assembly, secretion, or biological function of COL4A1. While we found no eQTLs for 
variants in LD with our lead SNPs in GTEX7 and GRASP2 there might be eQTLs in 
relevant tissues or cell types not captured by these sources. In keeping with the role of 
COL4A1 in small vessel disease we found rs9521634 to show the strongest association 
signal in SVS. Interestingly, common variants in the adjacent COL4A2 gene associate with 
SVS 
2, 17
, intracerebral hemorrhage
17
, and white matter hyperintensities.
18
 Collectively, 
these findings define COL4A1 and COL4A2 as key molecules in the biology of stroke and 
small vessel disease.  
 
Our association results in combination with the  eQTL data further point to a potential role 
of DYRK1A in stroke. DYRK1A encodes a dual-specificity tyrosine-phosphorylation-
regulated kinase 1A that has recently been shown to regulate angiogenic responses in 
vascular endothelial cells.
19
 Dyrk1a heterozygous mice exhibit defects in retinal 
vascularization and DYRK1A was found to positively regulate VEGF-dependent 
transcriptional responses in endothelial cells .
19
 We found no association signal with 
specific ischemic stroke subtypes possibly related to limited power. DYRK1A maps to the 
Down syndrome (DS) critical genetic region and is thought to contribute to the 
manifestations of DS. Recent work has drawn attention to an increased risk of stroke in 
DS.
20
 While this might relate to other factors our findings in conjunction with the above 
experimental data suggest a link between DYRK1 and stroke.  
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As a limitation, we were not able to perform meta-analyses for LAS, CES, and SVS with 
UKB since information on etiological subtypes of ischemic stroke  is not yet available in 
UKB. Also, the gain in power compared to MEGASTROKE was limited because of the 
relatively small number of stroke cases (around 5,000) in UKB, although numbers will 
increase with further follow-up.
13
 Nonetheless, we found three novel loci providing 
further insights into relevant stroke pathways and mechanisms. Integration of additional 
datasets will be key to better understanding the genetic basis of stroke. 
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 TABLES 
 
rsID rs1799983 rs9521634 rs720470 
Gene(s) NOS3 COL4A1 DYRK1A 
Risk allele/ reference allele T/G C/T T/C 
Risk allele frequency, % 32 36 71 
Phenotype AS AS AS 
Analysis EUR TRANS TRANS 
MEGASTROKE OR  
[95% CI] 
1.05  
[1.03-1.07] 
1.04  
[1.03-1.06] 
1.04 
 [1.02-1.06] 
UKB OR 
 [95% CI] 
1.06  
[1.02-1.11] 
1.05  
[1.01-1.09] 
1.11  
[1.07-1.17] 
Combined OR  
[95% CI] 
1.05  
[1.04-1.07] 
1.04  
[1.03-1.06] 
1.05  
[1.03-1.07] 
Combined P-value 2.2E-08 3.8E-08 6.1E-09 
 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
9 
 
 
 
Table 1  Results from the fixed effects (trans-ancestral and European-only) GWAS meta-analyses. For each 
locus the variant the lowest p-value in the fixed effects trans-ancestral or European-only meta-analysis, 
respectively, is shown . Chr, chromosome; TRANS, trans-ancestral fixed-effects meta-analysis; EUR, European-
only fixed-effects meta-analysis; OR, odds ratio; CI, confidence interval;   
 
 
FIGURE LEGENDS 
 
 
Figure 1 Manhattan plot and Regional Association Plots for the three novel risk loci 
identified in the current study . (A) Manhattan plot for any stroke in the trans-ancestral 
meta-analysis. The dotted line marks the threshold of genome-wide significance. Novel 
loci are marked on the top. Note that NOS3 reached genome-wide significance in the 
European-only analysis. (B to D) Regional Association Plots for lead variants at the three 
novel loci. (B) NOS3, (C) COL4A1 and (D) DYRK1A. Shown is the region for the top 
signal ± 500kb. The y-axis represents the –log(p-value) from the European-only fixed-
effects GWAS meta-analysis (NOS3) or trans-ancestral fixed-effects GWAS meta-analysis 
(COL4A1 and DYRK1A). Variants in LD with the lead variant are shown in red (r
2
>0.6), 
orange (r
2
>0.4), yellow (r
2
>0.2) and grey (r
2
<0.2). RAF; risk allele frequency 
 
Figure 2 Association of common variants in the NOS-NO signaling pathway with 
blood pressure and with any stroke. For each SNP in the NOS-NO signaling pathway, the 
effect for systolic blood pressure (SBP) (A) and diastolic blood pressure (DBP) (B) is displayed on the 
x-axis and the odds ratio (OR) for any stroke from the European-only analysis is displayed on the y-
axis together with their respective standard errors. The solid and dashed lines display the inverse 
variance weighted (IVW) effect estimate and 95% confidence interval (CI), respectively. Estimates for 
systolic and diastolic blood pressure were derived from UKB. Estimates for stroke were derived from 
inverse variance fixed effects meta-analyses of MEGASTROKE and UKB.
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